Amgen to sell new drug treatment

Amgen announced Nov. 21 that it has obtained the rights to Otezla, an oral treatment for plaque psoriasis and psoriatic arthritis.

Amgen acquired the drug in a $13.4-billion cash deal from Celgene Corporation in connection with Celgene’s previously announced merger with Bristol Myers Squibb Company.

The drug is a treatment for patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy, adult patients with ac...

Oops! An active online subscription is required to access this content.

Please login below or Subscribe today!